Our Research Group Publishes Study on an 11-Gene Panel for Nasopharyngeal Cancer Diagnosis and Prognosis

Our research group has published a study identifying 11 genes as potential biomarkers for diagnosing and predicting outcomes in nasopharyngeal carcinoma (NPC), a type of head and neck cancer common in regions such as Southeast Asia. The paper, titled "Integrative Transcriptomic Analysis Identifies an 11-Gene Signature for Diagnosis and Prognosis in Nasopharyngeal Carcinoma," appears in The Open Bioinformatics Journal (DOI: 10.2174/0118750362408821250821062122), published on August 23, 2025.

The analysis integrated transcriptomics data from three public datasets (GSE12452, GSE53819, and GSE102349) and applied survival modeling techniques, including the Cox proportional hazards model and Elastic Net regression. This approach yielded an 11-gene panel that divides patients into high- and low-risk groups for disease progression, with a log-rank p-value of 0.0035.

Of the genes, five (BUB1B, GAS2L3, NFE2L3, OIP5, and PDGFRL) are indicated as potential oncogenes, while six (CD1D, CYP4B1, IL33, KLF2, NAPSB, and VILL) show tumor-suppressor properties. Validation using the Cancer Cell Line Encyclopedia (CCLE) supported RNA expression and protein level consistency for six genes.

The study confirms some known biomarkers and introduces genes not previously reported in NPC. These findings may support improved diagnostic accuracy, prognostic grouping, and targeted therapy development for NPC patients.

As an open-access article, the publication is available to the scientific community. NPC is diagnosed in over 130,000 people globally each year.

Access the full paper: DOI: 10.2174/0118750362408821250821062122.

Lokasi: http://dx.doi.org/10.2174/0118750362408821250821062122